Globus Medical (GMED) Cash & Equivalents (2011 - 2026)

Globus Medical has reported Cash & Equivalents for 16 years, with the latest figure at $560.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 21.61% year-over-year to $560.9 million; the trailing twelve-month figure through Mar 2026 stood at $560.9 million (up 21.61% YoY), and the FY2025 full-year result was $526.2 million, down 32.93% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $560.9 million, up from $526.2 million in the prior quarter.
• The five-year high for Cash & Equivalents was $784.4 million in Q4 2024, with the low at $134.2 million in Q3 2022.
• Historically, Cash & Equivalents has averaged $368.1 million across 5 years, with a median of $354.1 million in 2024.
• Annual changes were most pronounced in 2022 — Cash & Equivalents tumbled 62.91% — and 2023, when it jumped 210.56%.
• Globus Medical's Cash & Equivalents stood at $150.5 million in 2022, then jumped by 210.56% to $467.3 million in 2023, then soared by 67.87% to $784.4 million in 2024, then plunged by 32.93% to $526.2 million in 2025, then grew by 6.61% to $560.9 million in 2026.
• The last three Cash & Equivalents figures came in at $560.9 million (Q1 2026), $526.2 million (Q4 2025), and $371.8 million (Q3 2025), per Business Quant data.